Abstract:The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 9.2 million confirmed cases and 478,000 deaths (as of June 24th, 2020). The high intensive care unit (ICU) admission rate and mortality of COVID-19 is continuously posing a serious strain on the global health-care system. While most patients present with mild to moderate symptoms, some patients may develop life-threatening sepsis, respiratory failure, acute respiratory distress syndrome (ARDS) and multiple organ failure. However, current antiviral and supportive therapies are not sufficient to prevent or treat the above complications especially in severely ill COVID-19 patients [1]. Thus, it is urgent to find the underlying mechanism dominating such life-threatening complications. It is well recognized that lung damage and multi-organ failure in this subgroup of patients arise due to overwhelming systemic hyper-inflammation. Therefore, promising anti-inflammatory candidate agents targeting diverse mechanisms related to cytokine storm will be therapeutically relevant (Fig. 1 ). Open in a separate window Fig. 1 Potential therapies of COVID-19 by targeting inflammation and cytokine storm. SARS-CoV-2 enters and infects cells by binding to TMPRSS2 and ACE2, subsequently releases virus RNA, one of the PAMPs, and recruits dendritic cells, macrophages and neutrophils. The released type I interferon and pro-inflammatory cytokines and chemokines induce the innate immune response while adaptive immune response is ignited by activating T and B lymphocytes to defend against the virus. Meanwhile, intact viruses or the components can directly activate the NLRP3 inflammasome, leading to IL-1β secretion. In most infections, moderate immune response and antiviral response are capable to combat the infection. Nevertheless, in individuals with immunological dysfunction, persistent hyper-inflammation triggers a cytokine storm, leading to the lung injury and ARDS or eventually swept through the whole body, causing MODS. During the pathological progression, the inhibition of NRLP3, JAK1/2, IL-6, BRD4 and the infusion of IVIG may be beneficial in suppressing the overwhelming inflammation and arrest or reverse the COVID-19 disease. Abbreviations: ACE2, angiotensin converting enzyme 2; ARDS, acute respiratory distress syndrome; IVIG, intravenous immunoglobulin; MODS, multiple organ dysfunction syndrome; NLRP3, Nod-like receptor protein 3; PAMP, pathogen-associated molecular pattern; TMPRSS2, transmembrane serine protease 2.

The mechanism of multiple organ dysfunction syndrome in patients with COVID-19

The Mechanism of Multiple Organ Dysfunction Syndrome in Patients with COVID‐19

Development of Multiple Organ Dysfunction Syndrome in Patients with Coronavirus Disease 2019: Clinical Characteristics and Risk Factors

Multi-organ Dysfunction in Patients with COVID-19: A Systematic Review and Meta-analysis

[Clinical Analysis of Multiple Organ Dysfunction Syndrome in Patients Suffering from SARS].

COVID-19 and multiorgan failure: A narrative review on potential mechanisms

Severe COVID-19 Infection Associated with Endothelial Dysfunction Induces Multiple Organ Dysfunction: A Review of Therapeutic Interventions

Inflammation Triggered by SARS-CoV-2 and ACE2 Augment Drives Multiple Organ Failure of Severe COVID-19: Molecular Mechanisms and Implications

Comorbid Chronic Diseases and Acute Organ Injuries Are Strongly Correlated with Disease Severity and Mortality among COVID-19 Patients: A Systemic Review and Meta-Analysis

Targeting Inflammation and Cytokine Storm in COVID-19

The Molecular Mechanism of Multiple Organ Dysfunction and Targeted Intervention of COVID-19 Based on Time-Order Transcriptomic Analysis

[Clinical Epidemiology of 1,087 Patients with Multiple Organ Dysfunction Syndrome].

COVID-19 Severity is Associated with Immunopathology and Multi-Organ Damage

Clinical epidemiology of 1087 patients with multiple organ dysfunction syndrome

Multi-Organ Involvement in COVID-19: Beyond Pulmonary Manifestations

Multi-organ microphysiological system: A new paradigm for COVID-19 research

COVID-19 and the cardiovascular system: a study of pathophysiology and interpopulation variability

Wide Spectrum of Presentation and Variable Mechanisms of Compromised Cardiac Function in Multiple Organ Dysfunction Syndrome

Research Progress of Coagulation Dysfunction in Coronavirus Disease 2019

Alveolar Macrophage Dysfunction and Cytokine Storm in the Pathogenesis of Two Severe COVID-19 Patients.

Molecular and Cellular Mechanisms of Liver Dysfunction in COVID-19.